CClinicalTrials.gg
CompletedNCT03535623Updated Jun 11, 2026Results posted

RIPC During Free Flap With Preoperative Radiotherapy

An interventional study of remote ischemic preconditioning (RIPC) and Sham-RIPC in Ischemic Reperfusion Injury, Other Reconstructive Surgery and Radiotherapy, sponsored by Seoul National University Hospital. Completed at 1 site in South Korea. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

Remote ischemic preconditioning (RIPC) has shown organ-protective effects in many clinical settings including patients with ischemic heart disease. However its protective role in head and neck cancer patients with preoperative radiotherapy undergoing free flap reconstructive surgery has not yet been evaluated. The purpose of the current study is to evaluate the effect of RIPC on tissue oxygen saturation and skin temperature of the flap.

Read the detailed description

Patients undergoing free flap reconstructive surgery for head and neck cancer with preoperative radiotherapy will be randomized to either remote ischemic preconditioning (RIPC) group or control group. On the day of surgery, after induction of anesthesia, RIPC, consisting of 4 cycles of 5-min ischemia (using pneumatic cuff pressure of 200 mmHg) followed by 5-min reperfusion at the upper arm, or sham-RIPC (pressure \< 10 mmHg) will be induced in the RIPC or control group, respectively. Before completion of surgery, RIPC or sham-RIPC will be repeated. Tissue oxygen saturation and skin temperature of the flap will be recorded until postoperative day 1.

02

Conditions studied

  • Ischemic Reperfusion Injury
  • Other Reconstructive Surgery
  • Radiotherapy

Keywords

  • remote ischemic preconditioning
  • free flap reconstruction
  • preoperative radiotherapy
03

In context

Lead sponsor

Seoul National University Hospital is the lead sponsor of 1,860 studies on the registry; 275 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adult head and neck cancer patients undergoing free flap reconstructive surgery with preoperative radiotherapy

Exclusion criteria

Exclusion Criteria:

  • Radiotherapy within 4 weeks
  • Body mass index \< 18 kg/m\^2 or > 35 kg/m\^2
  • Presence of AV fistula at the arm, any reason to protect arms
  • Presence of vascular abnormality or discomfort at arms
  • Peripheral vascular disease, peripheral neuropathy, or coagulopathy
  • Uncontrolled diabetes mellitus
  • Preoperative use of beta-blockers
  • Refuse to enrol
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    RIPC

    Remote ischemic preconditioning (RIPC) consisted of 4 cycles of 5-min ischemia using pneumatic cuff pressure of 200 mmHg and 5-min reperfusion is applied to the upper arm of the patients in the RIPC group.

    Other: remote ischemic preconditioning (RIPC)

  • Sham comparator
    Sham-RIPC

    Sham-RIPC consisted of 4 cycles of 5-min ischemia using pneumatic cuff pressure of \< 10 mmHg and 5-min reperfusion is applied to the upper arm of the patients in the Sham-RIPC group.

    Other: Sham-RIPC

Interventions

  • Otherremote ischemic preconditioning (RIPC)

    RIPC consists of 4 cycles of 5-min ischemia using pneumatic cuff pressure of 200 mmHg and 5-min reperfusion.

  • OtherSham-RIPC

    Sham-RIPC consists of 4 cycles of 5-min ischemia using pneumatic cuff pressure of \< 10 mmHg and 5-min reperfusion.

06

What researchers measure

Primary outcomes

  1. Tissue Oxygen Saturation

    tissue oxygen saturation of the flap

    Time frame: postoperative day 1

Secondary outcomes

  1. Number of Participants With Flap Complications

    Number of participants who occurred flap complications during the study period

    Time frame: during the study period until discharge, an average of 17.5 days

07

Results

Posted Jun 11, 2026

Participant flow

Participant flow — Overall Study
MilestoneRemote Ischemic ConditioningSham
Started2222
Completed2019
Not completed23

Outcome measures

PrimaryTissue Oxygen Saturation

tissue oxygen saturation of the flap

Time frame:
postoperative day 1
Reported as:
Median · percent
Tissue Oxygen Saturation
percentRemote Ischemic ConditioningSham
Tissue Oxygen Saturation87 (69 to 95)84 (74 to 93)
SecondaryNumber of Participants With Flap Complications

Number of participants who occurred flap complications during the study period

Time frame:
during the study period until discharge, an average of 17.5 days
Reported as:
Count of participants · Participants
Number of Participants With Flap Complications
ParticipantsRIPCSham-RIPC
Number of Participants With Flap Complications410

Adverse events

Collected over through study completion, an average of 17.5 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Remote Ischemic Conditioning0/20 (0%)0/20 (0%)0/20 (0%)
Sham0/19 (0%)0/19 (0%)0/19 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Remote Ischemic ConditioningShamTotal
Median65 (55 to 72)65 (59 to 69)65 (56 to 70)
Sex: Female, Male
Sex: Female, Male(Participants)Remote Ischemic ConditioningShamTotal
Female6511
Male141428
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Remote Ischemic ConditioningShamTotal
American Indian or Alaska Native000
Asian201939
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Remote Ischemic ConditioningShamTotal
South Korea201939
Regional tissue oxygen saturation
Regional tissue oxygen saturation(%)Remote Ischemic ConditioningShamTotal
Median87 (69 to 95)84 (74 to 93)85 (74 to 94)
08

Study locations

1 site
  • Seoul National University Hospital
    Seoul, 03080, South Korea
09

References and documents

Publications

  • Min S, Kim JE, Oh HM, Yoon SB, Ahn SH, Cho YJ. Effects of Remote Ischemic Conditioning on Flap Oxygenation in Patients Undergoing Head and Neck Reconstruction and Preoperative Radiotherapy: A Randomized Clinical Trial. J Oral Maxillofac Surg. 2025 Nov;83(11):1421-1430. doi: 10.1016/j.joms.2025.07.010. Epub 2025 Aug 5. PubMed 40846225 ↗

Study documents

  • Protocol and statistical analysis plan · Feb 9, 2026

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03535623
Lead sponsor
Seoul National University Hospital
Responsible party
Youn Joung Cho, MD, PhD (Clinical assistant professor, Seoul National University Hospital) — Principal investigator
First posted
May 24, 2018
Start date
May 29, 2018
Primary completion
Mar 20, 2024
Completion
Apr 18, 2024
Results posted
Jun 11, 2026
Last update
Jun 11, 2026

Study contacts

Youn Joung Cho, MD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion